Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• Structure Therapeutics reported a quarterly loss of ($0.36) EPS, falling short of analysts' expectations of ($0.28) by $0.08.
• After the earnings announcement, shares of Structure Therapeutics traded at $16.26, indicating a decline from a 50-day moving average of $19.89.
• Despite recent earnings miss, several analysts maintain a "buy" rating for the stock, with target prices ranging from $60.00 to $90.00.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08), Zacks reports.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded up $0.06 during midday trading on Friday, hitting $16.26. The company's stock had a trading volume of 785,636 shares, compared to its average volume of 872,055. The firm's fifty day moving average price is $19.89 and its 200-day moving average price is $21.93. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $45.37. The firm has a market cap of $932.23 million, a P/E ratio of -15.48 and a beta of -1.89.

Institutional Trading of Structure Therapeutics

A hedge fund recently raised its stake in Structure Therapeutics stock. Geode Capital Management LLC raised its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 18.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,181 shares of the company's stock after purchasing an additional 8,444 shares during the quarter. Geode Capital Management LLC owned about 0.09% of Structure Therapeutics worth $1,124,000 as of its most recent SEC filing. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Guggenheim dropped their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday. HC Wainwright dropped their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. JMP Securities reduced their target price on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $75.71.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.